Share This Author
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
- J. Murrough, D. Iosifescu, S. Mathew
- Psychology, MedicineAmerican Journal of Psychiatry
- 1 October 2013
Ketamine demonstrated rapid antidepressant effects in an optimized study design, further supporting NMDA receptor modulation as a novel mechanism for accelerated improvement in severe and chronic forms of depression.
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression
Ketamine for Depression: Where Do We Go from Here?
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.
- S. Mathew, J. Murrough, M. aan het Rot, K. Collins, D. Reich, D. Charney
- PsychologyInternational Journal of Neuropsychopharmacology
- 1 February 2010
This pilot study showed that a sub-anaesthetic dose of i.v. ketamine is well-tolerated in TRD, and may have rapid and sustained antidepressant properties, and riluzole did not prevent relapse in the first month following ketamine.
Neurobiological mechanisms in major depressive disorder
Data is discussed describing how genes, psychosocial adversity in childhood, and ongoing or recentPsychosocial stress may impact multiple neurobiological systems relevant to major depressive episodes.
Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.
- C. Haile, J. Murrough, S. Mathew
- Biology, PsychologyInternational Journal of Neuropsychopharmacology
- 1 February 2014
Data support plasma BDNF as a peripheral biomarker relevant to ketamine antidepressant response and associations with symptoms in patients with TRD enrolled in a randomized controlled trial of ketamine compared to an anaesthetic control (midazolam).
EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT‐RESISTANT DEPRESSION
In the first randomized controlled trial of ketamine using an anesthetic control condition, ketamine's acute effects on explicit suicidal cognition and a performance‐based index of implicit suicidal cognition (IAT) previously linked to suicidal behavior are tested.